[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564020":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":14,"locations":23,"responsibleParty":39,"collaborators":7,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",null,[9,12],{"name":10,"affiliation":5,"role":11},"Aiping Fang, MBBS, PhD","PRINCIPAL_INVESTIGATOR",{"name":13,"affiliation":5,"role":11},"Yanjun Zhang, MBBS, MD",[15,19],{"name":10,"role":16,"phone":17,"phoneExt":7,"email":18},"CONTACT","+86 20 87335189","fangaip@mail.sysu.edu.cn",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Yaojun Zhang, MBBS, MD","+86 20 87343117","zhangyuj@sysucc.org.cn",[24],{"facility":25,"status":7,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Sun Yat-sen University Cancer Center","Guangzhou","Guangdong","510060","China","CN",{"type":32,"coordinates":33},"Point",[34,35],113.25,23.11667,{"lat":35,"lon":34},[38],{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},{"type":11,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Aiping Fang","Associate Professor","100564020","liver-cancer-prognosis-investigation-study-100564020",false,"NCT06623734","Liver Cancer Prognosis Investigation Study","Liver CAncer PRognosis InvEstigation Study (Liver-CARE)","Inclusion Criteria:\n\n* Age 18-80 years,\n* Diagnosed with primary liver cancer (ICD-10: C22) (Referring to the diagnostic criteria in the \"Primary Liver Cancer Diagnosis and Treatment Guidelines (2024 Edition)\" and the \"2024 CSCO Guidelines for the Diagnosis and Treatment of Biliary Malignancies),\n* Have not received any anti-tumor treatment (e.g., surgery, ablation, interventional therapy, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc),\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Have a history of other malignant tumors,\n* Have a history of other serious chronic diseases (e.g., heart failure, liver failure, kidney failure, etc.),\n* Expected survival time is no more than 3 months,\n* Severe physical or mental disability.","ALL","18 Years","80 Years",{"count":53,"type":54},5000,"ESTIMATED","OBSERVATIONAL","This prospective cohort study is designed to explore the role of environmental, clinical, and genetic risk factors in the progression and prognosis of primary liver cancer (PLC). We will recruit 5000 patients with newly diagnosed, previously untreated PLC. The eligible patients will be asked to complete a baseline survey at the time of initial admission and be followed up every 3 to 6 months after discharge.",[58],"Liver Neoplasms",[60,61,62,63,64],"Primary liver cancer","Hepatocellular carcinoma","Intrahepatic cholangiocarcinoma","Prognosis","Prospective cohort study","NOT_YET_RECRUITING","2025-03-03",{"date":68,"type":69},"2025-03-06","ACTUAL",{"date":71,"type":54},"2025-04-01",{"date":73,"type":54},"2044-12-31",{"name":5,"class":6},1]